Trans-Chalcone prevents VEGF expression and retinal neovascularization in the ischemic retina

Experimental Eye Research

Volumn 93, Issue 4, 2011, Pages 350-354

  Lamoke, Folami ^a   Labazi, Mohamed ^a   Montemari, Annalisa ^b   Parisi, Giovanni ^b   Varano, Monica ^b   Bartoli, Manuela ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

Flavonoids; Retinal neovascularization; Trans Chalcone; Vascular endothelial growth factor

Indexed keywords

CHALCONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; STAT3 PROTEIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; MORPHOMETRICS; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION;

ANIMALS; ANIMALS, NEWBORN; ANTIOXIDANTS; BLOTTING, WESTERN; CHALCONES; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAPERITONEAL; INTERCELLULAR ADHESION MOLECULE-1; MICE; NF-KAPPA B; REPERFUSION INJURY; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80055038350     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.02.007     Document Type: Article

References (31)

1. Al-Shabrawey M., Bartoli M., El-Remessy A.B., Platt D.H., Matragoon S., Behzadian M.A., Caldwell R.W., Caldwell R.B. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am. J. Pathol. 2005, 167:599-607.
2. Bartoli M., Gu X., Tsai N.T., Venema R.C., Brooks S.E., Marrero M.B., Caldwell R.B. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J. Biol. Chem. 2000, 275:33189-33192.
3. Bartoli M., Platt D., Lemtalsi T. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003, 17:1562-1564.
4. Bartoli M., Al-Shabrawey M., Labazi M., Behzadian M.A., Istanboli M., El-Remessy A.B., Caldwell R.W., Marcus D.M., Caldwell R.B. HMG-CoA reductase inhibitors (statins) prevents retinal neovascularization in a model of oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2009, 10:4934-4940.
5. Brooks S.E., Gu X., Samuel S., Marcus D.M., Bartoli M., Huang P.L., Caldwell R.B. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest. Ophthalmol. Vis. Sci. 2001, 42:222-228.
6. Chew E.Y., Ferris F.L., Csaky K.G., Murphy R.P., Agrón E., Thompson D.J., Reed G.F., Schachat A.P. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 2003, 110:1683-1689.
7. Dimmock J.R., Elias D.W., Beazely M.A., Kandepu N.M. Bioactivities of chalcones. Curr. Med. Chem. 1999, 6:1125-1149.
8. Dixon R.A., Paiva N.L. Stress-Induced phenylpropanoid metabolism. Plant Cell. 1995, 7:1085-1097.
9. Ducki S. The development of chalcones as promising anticancer agents. IDrugs 2007, 10:42-46.
10. Ducki S. Antimitotic chalcones and related compounds as inhibitors of tubulin assembly. Anticancer Agents Med. Chem. 2009, 9:336-347.
11. Ducki S., Rennison D., Woo M., Kendall A., Chabert J.F., McGown A.T., Lawrence N.J. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity. Bioorg. Med. Chem. 2009, 17:7698-7710.
12. Edwards M.L., Stemerick D.M., Sunkara P.S. Chalcones: a new class of antimitotic agents. J. Med. Chem. 1990, 33:1948-1954.
13. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989, 161:851-858.
14. Gu X., Samuel S., El-Shabrawey M., Caldwell R.B., Bartoli M., Marcus D.M., Brooks S.E. Effects of sustained hyperoxia on revascularization in experimental retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2002, 43:496-502.
15. Haraguchi H., Ishikawa H., Mizutani K., Tamura Y., Kinoshita T. Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata. Bioorg. Med. Chem. 1998, 6:339-347.
16. Hsieh H.K., Lee T.H., Wang J.P., Wang J.J., Lin C.N. Synthesis and anti-inflammatory effect of chalcones and related compounds. Pharm. Res. 1998, 15:39-46.
17. Ishida S., Yamashiro K., Usui T., Kaji Y., Ogura Y., Hida T., Honda Y., Oguchi Y., Adamis A.P. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat. Med. 2003, 9:781-788.
18. Kalt W., Hanneken A., Milbury P., Tremblay F. Recent research on polyphenolics in vision and eye health. J. Agric. Food Chem. 2010, 58:4001-4007.
19. Lambert J.D., Hong J., Yang G., Liao J., Yang C.S. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am. J. Clin. Nutr. 2005, 81(Suppl. 1):S284-S291.
20. Liu Y.C., Hsieh C.W., Wu C.C., Wung B.S. Chalcone inhibits the activation of NF-kappaB and STAT3 in endothelial cells via endogenous electrophile. Life Sci. 2007, 80:1420-1430.
21. Lukiw W.J., Ottlecz A., Lambrou G., Grueninger M., Finley J., Thompson H.W., Bazan N.G. Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest. Ophthalmol. Vis. Sci. 2003, 44:4163-4170.
22. Madan B., Batra S., Ghosh B. 2'-hydroxychalcone inhibits nuclear factor kappa B and blocks tumor necrosis factor-alpha and lipopolysaccharide-induced adhesion of neutrophils to human umbilical vein endothelial cells. Mol. Pharmacol. 2000, 58:526-534.
23. Medina R.J., O'Neill C.L., Devine A.B., Gardiner T.A., Stitt A.W. The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS One 2008, 3:e2584.
24. Mezad-Koursh D., Goldstein M., Heilwail G., Zayit-Soudry S., Loewenstein A., Barak A. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina 2010, 30:1051-1057.
25. Nishijima K., Ng Y.S., Zhong L., Bradley J., Schubert W., Jo N., Akita J., Samuelsson S.J., Robinson G.S., Adamis A.P., Shima D.T. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 2007, 171:53-67.
26. Nowakowska Z. A review of anti infective and anti-inflammatory chalcones. Eur. J. Med. Chem. 2007, 42:125-137.
27. Penn J.S., Madan A., Caldwell R.B., Bartoli M., Caldwell R.W., Hartnett M.E. Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res. 2008, 27:331-371.
28. Platt D.H., Bartoli M., El-Remessy A.B., Al-Shabrawey M., Lemtalsi T., Fulton D., Caldwell R.B. Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3. Free Radic. Biol. Med. 2005, 39:1353-1361.
29. Rajappa M., Saxena P., Kaur J. Ocular angiogenesis: mechanisms and recent advances in therapy. Adv. Clin. Chem. 2010, 50:103-121.
30. Sapieha P., Hamel D., Shao Z., Rivera J.C., Zaniolo K., Joyal J.S., Chemtob S. Proliferative retinopathies: angiogenesis that blinds. Int. J. Biochem. Cell Biol. 2010, 42:5-12.
31. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'amato R., Sullivan R., D'Amato P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 1994, 35:101-111.